Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Status Not yet recruiting

Clinical Trial Summary

This study aims to investigate the safety and efficacy of radiotherapy combined with Toripalimab (PD-1 inhibitor) in the treatment of locally advanced adenocarcinoma of the gastroesophageal junction.

Clinical Trial Description

In this study, patients with locally advanced adenocarcinoma of gastroesophageal junction will be enrolled to explore the safety and efficacy of preoperative radiotherapy and chemotherapy combined with Toripalimab (PD-1). Around 45 patients will be recruited in this one-arm cohort. All patients in this cohort will be treated with preoperative radiotherapy and chemotherapy plus PD-1 for two times, then another two times of PD-1 before operation. After surgery, postoperative chemotherapy plus PD-1 will be carried out for four times. This study focuses on the safety of chemoradiotherapy combined with immunotherapy, and whether the TRG grade, LC, DFS have been improved. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04061928
Study type	Interventional
Source	Peking University
Contact	Jianhao Geng, MD
Phone	+86-18500227857
Email	gengjh3@sina.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	August 26, 2019
Completion date	August 25, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05161572` - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer	Phase 2
Completed	`NCT02399306` - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma	Phase 3
Recruiting	`NCT03286348` - Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer	N/A
Recruiting	`NCT04821765` - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer	Phase 2
Recruiting	`NCT04278287` - Chemoradiotherapy in Unresectable Esophageal Cancer	Phase 1/Phase 2
Recruiting	`NCT05863260` - Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
Active, not recruiting	`NCT05027165` - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Completed	`NCT04207918` - A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer	Phase 2
Recruiting	`NCT06219083` - Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy
Active, not recruiting	`NCT04764227` - Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)	Phase 2
Recruiting	`NCT06421376` - Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer	Phase 2
Recruiting	`NCT05311566` - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer	Phase 2
Not yet recruiting	`NCT05286086` - Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative	N/A
Recruiting	`NCT04772001` - Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer	N/A
Recruiting	`NCT06429839` - Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients	Phase 2
Recruiting	`NCT06410651` - Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT03177382` - Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors	Phase 3
Not yet recruiting	`NCT06413342` - Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT05590650` - A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients	Phase 1
Recruiting	`NCT00973778` - A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma	Phase 2